Incidence and impact of resistance against approved antiretroviral drugs. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Incidence and impact of resistance against approved antiretroviral drugs.

Rev Med Virol. 2000 Jul-Aug;10(4):231-53. Unique Identifier : AIDSLINE MED/20351800
Pillay D; Taylor S; Richman DD; PHLS Antiviral Susceptibility Reference Unit, Division of; Immunity and Infection, University of Birmingham, Medical School,; UK.


Abstract: More than 15 antiretroviral drugs are now available for clinical use, and have led to significant reductions in morbidity and mortality for HIV infected individuals. Nevertheless, antiviral drug resistance emerges to all these drugs, which limits their benefit. This review addresses the biological basis of antiretroviral drug resistance, and the prevalence of specific drug resistance associated mutations in patients treated with the three currently available classes of agents, namely nucleoside analogue reverse transcriptase inhibitors, non nucleoside reverse transcriptase inhibitors and protease inhibitors. In addition, data on prevalence of HIV drug resistance in untreated individuals published to date are summarised, and the implications of potential transmission of drug resistant HIV is discussed. Copyright 2000 John Wiley & Sons, Ltd.


Keywords: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Anti-HIV Agents/*PHARMACOLOGY/THERAPEUTIC USE Drug Resistance, Microbial Human HIV Infections/DRUG THERAPY/TRANSMISSION HIV-1/*DRUG EFFECTS/GENETICS Reverse Transcriptase Inhibitors/*PHARMACOLOGY/THERAPEUTIC USE

KWDjournalarticlereviewreview,tutorialanti-hivagents/KWDpharmacology/therapeuticusedrugresistance,microbialhumanhivinfections/drugtherapy/transmissionhiv-1/KWDdrugeffects/geneticsreversetranscriptaseinhibitors/KWDpharmacology/therapeuticuse
001130
A00B1152


Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .